Cited across angiogenesis, tendon-fibroblast, and GI-mucosa research literature
Protein and resistance training are the missing half
Abstract Background: Several clinical trials have demonstrated that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) reduce the incidence of non-fatal myocardial infarction (MI) in patients with type 2 diabetes mellitus (T2DM)
A Massachusetts Eye and Ear study found that: Patients with type 2 diabetes prescribed semaglutide were about 4 times more likely to develop NAION than those on other diabetes medications Patients who were overweight or obese and were prescribed semaglutide were over 7 times more likely to develop NAION than those on other weight-loss medications Because the warning labels on these medications may not have mentioned the risk of NAION, anyone who developed vision loss or blindness after taking Ozempic may be able to pursue compensation from a NAION semaglutide lawsuit
Belisle SE, Hamer DH, Leka LS, Dallal GE, Delgado-Lista J, Fine BC, et al
The Case for Optimism: Years of Compelling Data The optimism around GLP-1s and dementia is not speculative, it is data-driven
